Ablative fractional CO2 laser surgery improving sleep quality, pain and pruritus in adult hypertrophic scar patients: a prospective cohort study

Kaiyang Lv1,2,†,*, Huazhen Liu2,†, Haiting Xu3,4, Caixia Wang5, Shihui Zhu2, Xiaozhen Lou2, Pengfei Luo2, Shichu Xiao2,* and Zhaofan Xia2,*

1Department of Plastic Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092; People’s Republic of China, 2Department of Burn Surgery, the First affiliated Hospital to Naval Medical University, Shanghai 200433, People’s Republic of China, 3Department of Burn and Plastic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, People’s Republic of China, 4Department of Plastic Surgery, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, People’s Republic of China and 5Shanghai Institute of Laser Technology, Shanghai 200233, People’s Republic of China

*Correspondence. Kaiyang Lv, Email: lvkaiyang@hotmail.com; Shichu Xiao, Email: huangzhuoxiao4@hotmail.com; Zhaofan Xia, Email: xiazhaofan_smmu@163.com
†Joint first author.

Received 21 September 2020; Revised 20 October 2020; Editorial decision 10 May 2021

Abstract

Background: Poor sleep quality is associated with a decrease in quality of life in patients with major burn scars, combined with pruritus and pain. Few interventions have been reported to improve the sleep quality of patients with scars. In the current prospective cohort study, we investigated the efficacy of CO2-ablative fractional laser (AFL) surgery vs conventional surgery in post-burn patients with hypertrophic scars with sleep quality as the primary study outcome.

Methods: In total 68 consecutive patients undergoing scar surgical treatment were recruited, including a CO2-AFL surgery cohort (n = 35) and a conventional surgery cohort (n = 33). A subgroup from the AFL cohort was selected. Sleep quality, pain and pruritus were evaluated. Multiple linear regression analyses were performed to reveal the effect of CO2-AFL surgery.

Results: The CO2-AFL surgery cohort had significantly lower Pittsburgh sleep quality index (PSQI) global scores than the conventional surgery cohort after the last surgical treatment. In the subgroup of patients receiving hardware sleep monitoring, CO2-AFL markedly increased deep sleep time, deep sleep efficiency and reduced initial sleep latency. Compared to the conventional surgery cohort, the CO2-AFL cohort presented significantly lower pain and pruritus scores. Correlation analysis showed pain and pruritus were significantly associated with PSQI scores, and there were also significant correlations between pain and pruritus scores. Multiple linear regression analysis showed that surgery method was negatively linearly correlated with visual analog scale (VAS) pain score, brief pain inventory (BPI) total, VAS pruritus score, 5-D itch scale total, four-item itch questionnaire (FIIQ) total and PSQI total.
Conclusions: CO2-AFL surgery significantly improved sleep quality and reduced pain and pruritus of hypertrophic scar patients. The alleviation of sleep disorder was associated with improvement of deep sleep quality including deep sleep time and deep sleep deficiency.

Trial registration: The Chinese Clinical Trial Registry (ChiCTR200035268) approved retrospectively registration on 5 Aug 2020.

Key words: Burn scar, Ablative CO2 fractional laser, Cardiopulmonary coupling, Sleep quality, Pain, Pruritus

Highlights
• This study demonstrates for the first time that CO2-AFL surgery can significantly improve sleep quality, especially the deep sleep quality, of hypertrophic scar patients.
• CO2-AFL surgery significantly reduces pain and pruritus of hypertrophic scar patients.
• This study supports use of CO2-AFL treatment as an effective therapy for burn scar patients with sleep disorders.

Background
Hypertrophic scars following burn injury occur as a result of undue proliferation of fibroblasts and excessive collagen synthesis that lead to excessive deposition of the extracellular matrix and diminished collagen degradation during wound healing [1–3]; the incidence of pathologic scar formation frequently happens after a burn wound has healed [4]. Contracture of hypertrophic scars, which is often accompanied by intense pruritus and neuropathic pain, compromises the quality of life of burn victims [5], including the occurrence of sleep disturbance [6–8]. Sleep quality is related to health and affects the balance of and satisfaction with life, and disturbance of sleep quality may lead to feelings of tension, depression, anger, fatigue and confusion [9], even suicide of the victims.

Various therapies are used for hypertrophic scarring following burn injury including burn rehabilitation massage therapy, garment pressure therapy, steroid injection and surgical excision [10–14]. Ablative fractional laser (AFL) is a novel therapeutic method for scars [15]. It generates thermal energy that is deposited in columns through the epidermis and into the dermis. These columns are evenly spaced throughout the treatment area, with the intervening areas composed of untreated viable skin, and create microscopic treatment zones [16]. The thermal energy of fractional lasers results in persistent expression of heat shock proteins and induces the production of a cascade of cytokines and growth factors, stimulating collagen production and tissue remodeling and activating fibroblasts, thereby reducing scar thickness and improving skin elasticity. Moreover, the greater the pulse energy of the lasers, the greater the degree of tissue ablation and coagulation [17–22].

AFL has been proved to provide significant, sustained improvement of mature hypertrophic burn scars, but its effect on sleep quality has not been reported. In the current prospective cohort study, we investigated the efficacy of ablative fractional carbon dioxide laser (CO2-AFL) surgery vs conventional surgery in post-burn patients with hypertrophic scars, with sleep quality as the primary study outcome.

Methods
Study population
Single center data from a multicenter, prospective cohort study of risk factors for hypertrophic burn scars were analyzed [23]. This single center prospective study enrolled consecutive burn scar patients who received treatment at Changhai Hospital between May 2016 and April 2018. Patients with immature scars who were aged at least 18 years and whose time interval from burn to scar occurrence was <1 year were included. We excluded pregnant or lactating women, patients with current or recent cancer, severe systemic disease or keloids, or patients who were in a poor condition and cannot tolerate surgery under regional or general anesthesia, or had previous CO2-AFL surgery.

Patients were assigned to undergo CO2-AFL surgery or conventional surgery according to scar severity and patients’ intent. Scar severity was jointly decided by scar area of total body surface area (TBSA) and scar location. A subgroup was selected from the CO2-AFL surgery cohort according to the patients’ will to undergo preoperative and postoperative hardware sleep monitoring. All patients provided written informed consent to surgical treatment.

The study protocol was approved by the local ethics committee of Changhai Hospital (CHEC2014086). All study participants provided written informed consent to the study.

Surgery protocols
Surgeries were performed by at least two burn surgeons with >6 years of experience in burn surgery, and the sessions of surgeries were determined by effective negotiation between doctors and patients depending on the patients’ condition. Conventional surgery included scar excision and suturing, scar excision split thickness skin graft, full thickness skin graft, regional flap (e.g. V-Y plasty, and Z plasty), skin substitute and pedicle flaps. CO2-AFL surgery was performed in one session every 4–12 weeks (UltraPulse® Encore; Lumenis, Santa Clara, CA, USA), under general anesthesia, nerve
blocking anesthesia or lumbar anesthesia for large scars (scar surgery area >2% TBSA) or with topical 1% lidocaine cream for small scars (scar surgery area ≤2%TBSA). Large scars were treated with laser under the whole scar principle, which means all the scar area should be treated in one session of AFL surgery, and the laser should try to penetrate the bottom of the scar. Treatment depth was determined according to the estimated scar thickness [15,24]. Scars were treated in the single pulse mode, with non-overlapping pulses, at an energy density of 20–150 mJ corresponding to a treatment depth of 0.4–4 mm and treatment density of 3–5%. Immediately after laser treatment, topical compound betamethasone suspension (5 mg/mL) was applied to the surface of the treated scar. In addition, wound gel (Prontosan, B. Braun Medical Inc, Bethlehem, PA) was applied for 3–7 days for anti-infective purposes. Then, 3–10 days postoperatively, patients were allowed to receive pressure therapy. All patients received pressure therapy, silicone sheet/gel and rehabilitation therapy under the guidance of doctors during the study period.

Sleep quality and paresthetic symptom evaluation
The sleep quality of the cohort was evaluated using the Pittsburgh sleep quality index (PSQI) [25]. The PSQI has seven domains, including subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication and daytime dysfunction over the last month. Scoring of the answers in each domain is based on a 0–3 scale, whereby 3 reflects the negative extreme on the Likert Scale and the range of the global sum is 0–21.

Pain was evaluated using the visual analog scale (VAS) [26] and brief pain inventory (BPI) [27]. BPI has domains which measure pain intensity (four items, score 0–40) and pain interference with functioning (seven items, score 0–70), respectively.

Pruritus was evaluated using the VAS for pruritus [28], the 5-D itch scale [29] and the four-item itch questionnaire (FIIQ) [30]. The 5-D itch scale has five dimensions: duration, severity, direction, interference and distribution with a total score of 5–25. A higher score indicates greater pruritus. The FIIQ has four dimensions: pruritus location (score range 1–3), pruritus degree (score range 1–5), pruritus frequency (score range 1–5) and effect on sleep (score range 0–6). The minimum score is 3, indicating the mildest pruritus and the maximum score is 19, indicating the most intense pruritus.

Evaluation of sleep quality and paresthetic symptoms, including pain and pruritus, by scales were also performed for data analysis, including 35 patients receiving CO2-AFL surgery and 33 patients undergoing conventional surgery. Patient demographic and baseline characteristics are shown in Table 1. The two groups were comparable in demographic and baseline characteristics except for sex distribution. The treatment area of the CO2-AFL surgery group is larger than that of the conventional surgery group (CO2-AFL surgery vs conventional surgery: 30.14 ± 17.01% vs 9.15 ± 5.04% TBSA, p < 0.001). A total of 14 patients were included in the subgroup of patients receiving CO2-AFL surgery whose sleep quality was assessed both preoperatively and postoperatively. Subgroup demographics and baseline characteristics are shown in Table 1.

Results
Patient demographic and baseline characteristics
The study flowchart is shown in Figure S1, see online supplementary material. In total, 68 patients were eligible for data analysis, including 35 patients receiving CO2-AFL surgery and 33 patients undergoing conventional surgery. Patient demographics and baseline characteristics are shown in Table 1. The two groups were comparable in demographic and baseline characteristics except for sex distribution. The treatment area of the CO2-AFL surgery group is larger than that of the conventional surgery group (CO2-AFL surgery vs conventional surgery: 30.14 ± 17.01% vs 9.15 ± 5.04% TBSA, p < 0.001). A total of 14 patients were included in the subgroup of patients receiving CO2-AFL surgery whose sleep quality was assessed both preoperatively and postoperatively.

Primary outcomes
PSQI The CO2-AFL surgery cohort had significantly lower PSQI global scores than the conventional surgery cohort (CO2-AFL surgery vs conventional surgery: 8.14 ± 3.67 vs 11.58 ± 4.89, p = 0.002) 4–6 weeks after the last surgical treatment (Table 2). Moreover, patients receiving CO2-AFL surgery had markedly lower scores in sleep quality (CO2-AFL
Table 1. Demographic characteristics of the study population and subgroup receiving objective sleep monitoring

| Variable                        | Conventional therapy (n = 33) | CO₂-AFL (n = 35) | CO₂-AFL subgroup (n = 14) |
|---------------------------------|-------------------------------|------------------|---------------------------|
| Male (n)                        | 16                            | 27**             | 12                        |
| Age (years)                     | 43.06 ± 11.34                 | 38.60 ± 10.78    | 38.07 ± 12.35             |
| BMI (kg/m²)                     | 23.83 ± 3.28                  | 23.13 ± 2.63     | 22.24 ± 2.86              |
| Burn area (%TBSA) (mean ± SD)   | 51.67 ± 22.73                 | 48.80 ± 24.41    | 50.93 ± 25.49             |
| Time interval from burn to surgery (months) (mean ± SD) | 6.68 ± 5.55 | 8.28 ± 6.41 | 7.56 ± 5.33 |
| Causes of injury (n)            |                               |                  |                           |
| Flame                           | 24                            | 32               | 10                        |
| Others                          | 9                             | 3                | 4                         |
| Scar location (n)               |                               |                  |                           |
| Head and face                   | 19                            | 26               | 12                        |
| Trunk                           | 27                            | 30               | 12                        |
| Extremities                     | 30                            | 30               | 13                        |
| Total session of treatments (mean ± SD) | 2.58 ± 1.47       | 2.43 ± 1.65     | 3.07 ± 2.16               |
| Treatment area (%TBSA) (mean ± SD) | 9.15 ± 5.04       | 30.14 ± 17.01** | 34.29 ± 16.56           |
| Postoperative local infections (n) | 6                          | 5               | 2                         |

**p < 0.01 compared with conventional therapy group. BMI body mass index (kg/m²), TBSA total body surface area, AFL ablative fractional laser, SD standard deviation.

surgery vs conventional surgery: 1,1–2 vs 2,1–2, p = 0.011), sleep latency (CO₂-AFL surgery vs conventional surgery: 2,1–2 vs 2,1–3, p = 0.009), sleep disturbances (CO₂-AFL surgery vs conventional surgery: 1,1–2 vs 2,1–3, p = 0.010), sleep time (CO₂-AFL surgery vs conventional surgery: 1.25 ± 1.07 vs 1.79 ± 1.05, p = 0.043) and daytime dysfunction (CO₂-AFL surgery vs conventional surgery: 1,1–2 vs 2,1–3, p = 0.013), which indicates better sleep quality (Table 2).

In the subgroup of patients receiving CO₂-AFL surgery whose sleep quality was assessed both preoperatively and postoperatively, the postoperative PSQI global score decreased significantly vs the baseline PSQI global score (preoperative vs postoperative: 12.60 ± 3.27 vs 8.86 ± 2.50, p < 0.001) (Table 2), suggesting improved sleep quality. In addition, the domain scores in sleep quality (preoperative vs postoperative: 2.14 ± 0.66 vs 1.36 ± 0.63, p = 0.001), sleep time (preoperative vs postoperative: 2.21 ± 0.97 vs 1.43 ± 0.94, p = 0.006), sleep efficiency (preoperative vs postoperative: 2.43 ± 0.76 vs 1.29 ± 0.91, p = 0.004) and sleep disturbances (preoperative vs postoperative: 1.93 ± 0.73 vs 1.29 ± 0.61, p = 0.022) decreased markedly after CO₂-AFL surgery. Meanwhile, there was no noticeable change in sleep latency (preoperative vs postoperative: 2.14 ± 1.03 vs 1.71 ± 0.91, p = 0.082), use of sleep medications (preoperative vs postoperative: 0 ± 0 vs 0.07 ± 0.27, p = 0.336) and daytime dysfunction (preoperative vs postoperative: 1.79 ± 0.7 vs 1.57 ± 0.76, p = 0.272) (Table 2).

Subgroup hardware sleep monitoring

In the subgroup of patients who underwent sleep monitoring by ECG hardware, total time in bed (preoperative vs postoperative: 10.41 ± 1.39 vs 9.70 ± 1.35, p = 0.017), initial enter deep sleep time (preoperative vs postoperative: 2.20 ± 2.01 vs 1.41 ± 1.66, P = 0.03), awakening time (preoperative vs postoperative: 1.61 ± 0.80 vs 0.78 ± 0.47, p < 0.001) and REM sleep time (preoperative vs postoperative: 1.97 ± 0.62 vs 1.54 ± 0.68, p = 0.014) decreased significantly after CO₂-AFL surgery (Table 2). Meanwhile, no marked change was observed in total sleep time (preoperative vs postoperative: 8.20 ± 1.21 vs 8.69 ± 1.31, p = 0.289), light sleep time (preoperative vs postoperative: 4.00 ± 1.56 vs 4.22 ± 1.69, p = 0.566), apnea index (preoperative vs postoperative: 14.93 ± 13.92 vs 18.33 ± 16.90, p = 0.272) and light sleep efficiency (preoperative vs postoperative: 0.41 ± 0.16 vs 0.46 ± 0.19, p = 0.128). Moreover, CO₂-AFL surgery significantly improved sleep efficiency (preoperative vs postoperative: 0.82 ± 0.08 vs 0.91 ± 0.05, p = 0.001), deep sleep efficiency (preoperative vs postoperative: 0.22 ± 0.10 vs 0.30 ± 0.15, p = 0.02) and deep sleep time (preoperative vs postoperative: 2.16 ± 1.06 vs 2.94 ± 1.53, p = 0.026) (Table 2).

Secondary outcomes

Pain

Compared to patients undergoing conventional surgery, patients receiving CO₂-AFL had significantly lower VAS pain score (CO₂-AFL surgery vs conventional surgery: 2.65 ± 1.39 vs 4.12 ± 2.33, p = 0.002) after the last treatment (Figure 1). Consistently, evaluation with BPI showed BPI global score (CO₂-AFL surgery vs conventional surgery: 27.94 ± 18.20 vs 42.94 ± 24.62, p = 0.006), pain intensity (CO₂-AFL surgery vs conventional surgery: 10.17 ± 7.13 vs 15.15 ± 9.54, p = 0.017) and pain interference with life (CO₂-AFL surgery vs conventional surgery: 17.77 ± 11.41 vs 27.79 ± 15.63, p = 0.003) were significantly less severe than in patients undergoing conventional surgery (Figure 1).
also had markedly lower scores in duration (CO2-AFL surgery: 12.34 ± 3.91 vs postoperative: 19.93 ± 3.91 (Figure 1). In addition, patients receiving CO2-AFL had markedly lower VAS pruritus score than patients receiving conventional surgery (CO2-AFL surgery: 3.58 ± 0.70 vs conventional surgery: 12.66 ± 4.14, p = 0.001). Moreover, patients receiving CO2-AFL had significantly lower scores of pruritus frequency and severity (CO2-AFL surgery vs conventional surgery: 2.2, 2–3 vs 3, 3–4, p = 0.002) and pruritus degree (CO2-AFL surgery vs conventional surgery: 2, 2–3 vs 3, 3–4, p = 0.018) and effect on sleep (CO2-AFL surgery vs conventional surgery: 4, 0–4 vs 4, 4–6, p = 0.001) than patients receiving conventional surgery (Table 3).

In the subgroup of patients receiving CO2-AFL surgery whose pruritus was assessed both preoperatively and postoperatively, CO2-AFL surgery markedly reduced VAS pruritus score (preoperative vs postoperative: 6.00 ± 1.41 vs 4.07 ± 1.21, p < 0.001) (Table 3). CO2-AFL surgery also significantly decreased the 5-D itch scale global score (preoperative vs postoperative: 17.36 ± 3.20 vs 13.64 ± 4.01, p = 0.002) and markedly shortened the duration (preoperative vs postoperative: 3.07 ± 1.07 vs 2.14 ± 1.29, p = 0.002), while significantly reducing severity (preoperative vs postoperative: 3.21 ± 0.70 vs 2.64 ± 0.84, p = 0.026), direction (preoperative vs postoperative: 4.00 ± 0.96 vs 2.93 ± 1.00, p = 0.002) and interference (preoperative vs postoperative: 4.29 ± 0.73 vs 3.43 ± 1.34, p = 0.003) (Table 3). Meanwhile, CO2-AFL surgery significantly decreased FIIQ global score (preoperative vs postoperative: 12.86 ± 2.96 vs 10.21 ± 2.08, p = 0.001), pruritus degree (preoperative vs postoperative: 3.29 ± 1.07 vs 2.36 ± 0.63, p = 0.001), pruritus frequency (preoperative vs postoperative: 3.29 ± 0.83 vs 2.64 ± 0.74,

### Table 2. Sleep parameters of the study cohorts and the subgroup*  

| Variables                      | CO2-AFL surgery (n = 35) | Conventional surgery (n = 33) | Subgroup preoperative (n = 14) | Subgroup postoperative (n = 14) |
|--------------------------------|--------------------------|-------------------------------|--------------------------------|--------------------------------|
| **PSQI Scales**                |                          |                               |                                |                                |
| global score                   | 8.14 ± 3.67              | 11.58 ± 4.89**                | 12.60 ± 3.27                   | 8.86 ± 2.50***                 |
| sleep quality                  | 1.1–2                    | 2.1–2–3*                      | 2.14 ± 0.66                    | 1.36 ± 0.63**                  |
| sleep latency                  | 2.1–2                    | 2.1–3**                       | 2.14 ± 1.03                    | 1.71 ± 0.91                   |
| sleep time                     | 1.25 ± 1.07              | 1.79 ± 1.05*                  | 2.21 ± 0.97                    | 1.43 ± 0.94**                  |
| sleep efficiency               | 2.1–2                    | 2.0–3                         | 2.43 ± 0.76                    | 1.29 ± 0.91**                  |
| sleep disturbances             | 1.1–2                    | 2.1–3*                        | 1.93 ± 0.73                    | 1.29 ± 0.61*                   |
| sleep medications              | 0.0–0                    | 0.0–0                         | 0 ± 0                          | 0.07 ± 0.27                    |
| daytime dysfunction            | 1.1–2                    | 2.1–3*                        | 1.79 ± 0.70                    | 1.57 ± 0.76                    |
| **Objective Sleep Monitoring** |                          |                               |                                |                                |
| total time in bed (hour)       | N/A                      | N/A                           | 10.41 ± 1.39                   | 9.70 ± 1.35*                   |
| total sleep time (hour)        | N/A                      | N/A                           | 8.20 ± 1.21                    | 8.69 ± 1.31                    |
| initial enter deep sleep time  | N/A                      | N/A                           | 2.20 ± 2.01                    | 1.41 ± 1.66*                   |
| deep sleep time (hour)         | N/A                      | N/A                           | 2.16 ± 1.06                    | 2.94 ± 1.53*                   |
| light sleep time (hour)        | N/A                      | N/A                           | 4.00 ± 1.36                    | 4.22 ± 1.69                    |
| REM sleep time (hour)          | N/A                      | N/A                           | 1.97 ± 0.62                    | 1.54 ± 0.68*                   |
| awakening time (hour)          | N/A                      | N/A                           | 1.61 ± 0.80                    | 0.78 ± 0.47***                 |
| sleep efficiency               | N/A                      | N/A                           | 0.82 ± 0.08                    | 0.91 ± 0.05**                  |
| deep sleep efficiency          | N/A                      | N/A                           | 0.22 ± 0.10                    | 0.30 ± 0.15*                   |
| light sleep efficiency         | N/A                      | N/A                           | 0.41 ± 0.16                    | 0.46 ± 0.19                    |
| apnea index (events per hour)  | N/A                      | N/A                           | 14.93 ± 13.92                  | 18.33 ± 16.90                  |

* Analysis for sleep quality, sleep latency, sleep efficiency, sleep disturbances, sleep medications and daytime dysfunction compared with CO2-AFL surgery were performed with Mann—Whitney U test. Analysis for global score and sleep time compared with CO2-AFL surgery were performed with independent sample t test. In the subgroup, analysis for sleep parameters compared with preoperative were performed with paired sample t test.

Data are presented as median, IQR or mean±SD.

p<0.05, **p<0.01 compared with CO2-AFL surgery; *p<0.05, ###p<0.01 compared with preoperative.

**PSQI** Pittsburgh Sleep Quality Index, IQR interquartile range, SD standard deviation, **AFL** ablative fractional laser, **REM** rapid eye movement, N/A not applicable.

In the subgroup of patients receiving CO2-AFL surgery, the postoperative VAS pain score was significantly lower vs baseline (preoperative vs postoperative: 5.57 ± 2.14 vs 3.29 ± 1.33, p < 0.001) (Figure 1). Evaluation with BPI revealed that CO2-AFL surgery markedly reduced BPI global score (preoperative vs postoperative: 54.00 ± 18.56 vs 39.00 ± 13.79, p < 0.001), pain intensity (preoperative vs postoperative: 19.93 ± 7.25 vs 14.36 ± 5.83, p = 0.001) and pain interference with functioning (preoperative vs postoperative: 34.07 ± 11.83 vs 24.64 ± 8.21, p = 0.001) (Figure 1).

**Pruritus** Patients receiving CO2-AFL had significantly lower VAS pruritus score than patients receiving conventional surgery (CO2-AFL surgery vs conventional surgery: 3.57 ± 1.36 vs 5.82 ± 1.86, p < 0.001) (Table 3). In addition, patients receiving CO2-AFL had markedly lower 5-D itch scale global score than patients undergoing conventional surgery (CO2-AFL surgery vs conventional surgery: 12.34 ± 3.91 vs 15.06 ± 4.02, p = 0.006). They also had markedly lower scores in duration (CO2-AFL surgery vs conventional surgery: 1, 1–2 vs 2, 2–3, p = 0.008), severity (CO2-AFL surgery vs conventional surgery: 2, 2–3 vs 3, 3–4, p = 0.007) and interference (CO2-AFL surgery vs conventional surgery: 4, 2–4 vs 5, 4–5, p = 0.002) than patients receiving conventional surgeries (Table 3).

Patients receiving CO2-AFL had significantly lower FIIQ global score than patients receiving conventional surgery (CO2-AFL surgery vs conventional surgery: 9.54 ± 3.58 vs 12.66 ± 4.14, p = 0.001). Moreover, patients receiving CO2-AFL had significantly lower scores of pruritus frequency (CO2-AFL surgery vs conventional surgery: 2, 2–3 vs 3, 3–4, p = 0.002), pruritus degree (CO2-AFL surgery vs conventional surgery: 2, 2–3 vs 3, 3–4, p = 0.018) and effect on sleep (CO2-AFL surgery vs conventional surgery: 4, 0–4 vs 4, 4–6, p = 0.001) than patients receiving conventional surgery (Table 3).
Figure 1. Pain scores of patients receiving CO2-AFL surgery, conventional surgery and the subgroup who underwent sleep monitoring by cardiopulmonary coupling before and after CO2-AFL surgery. (a) VAS scores of patients receiving CO2-AFL surgery (n = 35) vs patients undergoing conventional surgery (n = 33), (b) BPI scores of patients receiving CO2-AFL surgery (n = 35) vs patients undergoing conventional surgery (n = 33), (c) VAS scores of subgroup patients (n = 14), (d) BPI scores of subgroup patients (n = 14). *p < 0.05, **p < 0.01, ***p < 0.001. AFL ablative fractional laser, VAS visual analogue scale, BPI brief pain inventory

Table 3. Pruritus evaluation of the study cohort and the subgroup

| Variable                      | CO2-AFL surgery (n = 35) | Conventional surgery (n = 33) | Subgroup preoperative (n = 14) | Subgroup postoperative (n = 14) |
|-------------------------------|--------------------------|-------------------------------|-------------------------------|-------------------------------|
| VAS for pruritus              | 3.57 ± 1.36              | 5.82 ± 1.86***                | 6.00 ± 1.41                   | 4.07 ± 1.21***                 |
| 5-D scale                     |                          |                               |                               |                               |
| Global score                  | 12.34 ± 3.91             | 15.06 ± 4.02**                | 17.36 ± 3.20                  | 13.64 ± 4.01***                |
| Duration                      | 1.1–2                    | 2.2–3**                      | 3.07 ± 1.07                   | 2.14 ± 1.29**                  |
| Severity                      | 2.2–3                    | 3.2–3**                      | 3.21 ± 0.70                   | 2.64 ± 0.84*                   |
| Direction                     | 3.2–4                    | 3.3–3                        | 4.00 ± 0.96                   | 2.93 ± 1.00*                   |
| Interference                  | 4.2–4                    | 5.4–5**                      | 4.29 ± 0.73                   | 3.43 ± 1.34***                 |
| Distribution                  | 2.06 ± 1.16              | 2.61 ± 1.20                  | 2.64 ± 0.84                   | 2.50 ± 1.09                    |
| FIIQ                          |                          |                               |                               |                               |
| Global score                  | 9.54 ± 3.58              | 12.66 ± 4.14**               | 12.86 ± 2.96                  | 10.21 ± 2.08**                 |
| Pruritus location             | 2.1–3                    | 2.2–3                        | 2.29 ± 0.73                   | 2.29 ± 0.73                    |
| Pruritus degree               | 2.2–3                    | 3.2–3*                       | 3.29 ± 1.07                   | 2.36 ± 0.63**                  |
| Pruritus frequency            | 2.2–3                    | 3.3–4**                      | 3.29 ± 0.83                   | 2.64 ± 0.74*                   |
| Effect on sleep               | 4.0–4                    | 4.4–6**                      | 4.29 ± 1.73                   | 3.00 ± 1.30**                  |

*Analysis for duration, severity, direction, interference, pruritus location, pruritus degree, pruritus frequency and effect on sleep compared with CO2-AFL surgery were performed with Mann-Whitney U test. Analysis for VAS for pruritus, 5-D scale (global score and distribution) and FIIQ (global score) compared with CO2-AFL surgery were performed with independent sample t test. In the subgroup, analysis for pruritus evaluation variables compared with preoperative were performed with paired sample t test.

Data are presented as median, IQR or mean±SD.

*p<0.05, **p<0.01 compared with CO2-AFL surgery; *p<0.05, **p<0.01, ***p<0.001 compared with preoperative.

VAS visual analogue scale, FIIQ four-item itch questionnaire, IQR interquartile range, SD standard deviation, AFL ablative fractional laser.
Correlation analysis between paresthetic symptoms (pain and pruritus) and PSQI
Table S1, see online supplementary material, shows correlations between paresthetic symptoms (pain and pruritus) and PSQI (total and subscales) scores. All items of pain scores showed significant positive correlations with total PSQI score ($p < 0.001$). All PSQI items except use of sleep medication were significantly positively associated with pain scores.

All items of pruritus scores also showed significant positive correlations with total PSQI score ($p < 0.01$). All global scores of 5-D itch scale and FIIQ were significantly positively associated with all the PSQI items except habitual sleep efficiency.

Table 4 shows correlations between paresthetic symptoms of pain and pruritus. All items of pain scores showed significant positive correlations with all items of pruritus scores ($p < 0.01$). All items of pain scores also showed strong positive correlations with VAS pruritus scores, global score of 5-D itch scale and global score of FIIQ ($p < 0.01$).

The effect of CO$_2$-AFL surgery on sleep quality and paresthetic symptoms (pain and pruritus)
Table 5 shows the results of multivariate linear regression analysis for VAS pain score, BPI total score, VAS pruritus score, 5-D itch scale total score, FIIQ total score and PSQI total score, respectively, with surgery method, age, sex, burn scar area, BMI and time from burn to surgery included as independent variables. The results show that surgery method was negatively linearly correlated with VAS pain score, BPI total score, VAS pruritus score, 5-D itch scale total score, FIIQ total score and PSQI total score. For the conventional therapy cohort was labeled as 0 and CO$_2$-AFL cohort was labeled as 1 in multiple linear regression analysis, the results means AFL surgery was negatively association with sleep disorder and paresthetic symptoms, and both sleep disorder and paresthetic symptoms were improved in patients receiving AFL surgery. Age was a risk factor for increase in VAS pain score, BPI total score and 5-D itch scale total score, which means older patients with burn scar were susceptible to worse paresthetic conditions.

Discussion
Burn victims with hypertrophic scars are frequently afflicted with sleep disorders, pain and pruritus [34,35], which is associated with poor quality of life [3]. Our investigation presents the first clinical evidence that CO$_2$-AFL surgery significantly improved sleep quality of burn patients with hypertrophic scars. Patients also experienced significant improvement in pain and pruritus, which has also been previously reported...
sleep quality. On the other hand, evaluation by PSQI showed that CO2-AFL surgery was more effective than conventional surgery in decreasing PSQI global scores. In the subgroup analysis, CO2-AFL surgery also caused a significant reduction in VAS pain scores, which may be partly clinically explain the sleep quality improvement.

Our study compared the effect of CO2-AFL surgery vs conventional surgery on hypertrophic scar patients and found that CO2-AFL surgery was more effective than conventional surgery in decreasing PSQI global scores. In the subgroup study, CO2-AFL surgery also caused a significant reduction in the postoperative PSQI global score vs the baseline. To find the internal mechanism of sleep scale improvement, we performed sleep monitoring of the subset of patients via cardiopulmonary coupling hardware, which demonstrated that CO2-AFL surgery significantly improved the sleep efficiency, with reduced total time in bed, initial sleep latency, REM sleep time and awakening time. All the above parameters may contribute to the improvement in sleep efficiency and deep sleep efficiency. It suggested that CO2-AFL surgery improves the sleep quality by improving the deep sleep quality, including deep sleep time and deep sleep deficiency, rather than the light sleep quality. On the other hand, evaluation by PSQI showed that these patients exhibited no significant change in sleep efficiency between the CO2-AFL surgery cohort and the conventional surgery cohort. The discrepancy in sleep latency by PSQI and cardiopulmonary coupling monitoring could be explained by the greater sensitivity of real time monitoring via cardiopulmonary coupling hardware.

As correlation analysis showed, pain and pruritus of the scar sites could significantly interfere with sleep quality (Table S1) [37], which means alleviation of pain and pruritus could help to improve the sleep quality of patients. The multiple linear regression analysis showed that surgery method had a negative association with sleep quality scores and paresthetic symptom scores, and both sleep disorder and paresthetic symptoms were improved in patients who received AFL surgery, which confirms the beneficial effects of AFL surgery for patients with large areas of burn scars.

We found that CO2-AFL surgery was significantly more effective than conventional surgery in reducing pain intensity and interference with daily life by pain, and also caused a significant decrement of VAS pain scores, which may be associated with improving sleep quality in hypertrophic scar patients. Pruritus could also adversely impact on quality of life and interfere with a patient’s sleep [36]. Our study showed that CO2-AFL was significantly more effective than conventional surgery in alleviating VAS for pruritus. It was also more effective in reducing duration, severity and interference of pruritus while having no impact on distribution between the two cohorts. The correlation analysis between pain scores and pruritus scores showed there were comprehensive positive correlations between all items of pain and pruritus scores, which means the combination of pain and pruritus may aggravate the symptoms of sleep disorders and make them more difficult to correct, making it more reasonable that interventions improving pain and pruritus could also improve sleep disorders.

The mechanism of scar pain and pruritus is associated with the inflammatory response and proliferation of the vasculature of hypertrophic scars [7]. CO2-AFL could lead to apoptosis of fibroblasts in the microthermal zones and down-regulation of transforming growth factors and basic fibroblast growth factor [19,38], which would accelerate the maturation of hypertrophic scars, reducing the inflammatory response and decreasing the proliferation of the vasculature and the edema associated with the scar tissue (Figure 2). It is reasonable to accept that AFL is effective in the treatment of pain and pruritus of hypertrophic scars, though the exact mechanism still needs further research.

We also attribute the effect of AFL on the improvement of pain and pruritus of hypertrophic scars to the laser-assisted delivery of corticosteroid (a betamethasone suspension in our study), which enhances the effect of AFL treatment on hypertrophic scars [39,40]. Besides, full area of scars AFL treatment usually treat the area of the scar as large as possible in a single session and made a larger treatment area of CO2-AFL group than conventional therapy group, which would lead to a better outcome of the CO2-AFL group.

Our study still has some limitations. First, all the patients are from a single center, limiting the sample size of our final cohort. Nevertheless, we were able to demonstrate statistical
improvement in sleep disorder and paresthetic symptoms in the relatively small cohort. Second, randomized and blinded methods were not applied in this study, which would increase the bias of the study, potentially influencing the grading of the sleep quality and paresthetic symptoms of scars by both providers and patients. We remind readers to bear this in mind when applying the conclusions of the study.

Conclusions
Our study has demonstrated that CO2-AFL surgery significantly improved sleep quality, especially deep sleep quality, and reduced pain and pruritus of hypertrophic scar patients, which may provide an effective tool to improve the quality of life and sleep quality of the population with large area immature burn scars. Together with previous studies focused on mature scar treatment, we consider CO2-AFL treatment as an effective treatment for the whole course of scar proliferation.

Abbreviations
AFL: Ablative fractional laser; BMI: body mass index; BPI: brief pain inventory; ECG: Electrocardiogram; FIHQ: four-item itch questionnaire; IQR: Interquartile range; PSQI: Pittsburgh sleep quality index; REM: Rapid eye movement; TBSA: Total body surface area; VAS: Visual analogue scale.

Acknowledgments
We would like to thank Gao Qin and Zou Yinrui from Xinhua Harvard International Healthcare Innovation Collaboration Initiatives for manuscript discussion and review.

Funding
This work was supported by the Special Scientific Research Fund of the Public Welfare Profession of China (201502028), the Excellent Discipline Leader Training Program of Shanghai Health System (No.2017BR037), the National Natural Science Foundation of China (No.81772091), Clinical Research Plan of Shanghai Hospital Development Center (No. SHDC2020CR3039B) and Shanghai Rising-Star Program (17QB1403300).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
KL, SX and ZX designed the study. All authors managed the study with regard to surgery, patient care and data collection. KL and HL analysed the data, which was interpreted by all other authors. KL and HL wrote the first draft of the manuscript which was reviewed, modified and approved by all other authors. All the authors vouch for the accuracy and completeness of the data reported and for the fidelity of the study to the protocol.

Ethics approval and consent to participate
The study protocol was approved by the local ethics committee of Changhai Hospital (CHEC2014086). All study participants provided written informed consent to the study.

Consent for publication
Informed consent has been obtained from the subjects (or their guardians) as specified in the ICMJE recommendations.

Conflict of interest
None declared.

References
1. Tredget EE, Shupp JW, Schneider JC. Scar management following burn injury. J Burn Care Res. 2017;38:146-7.
2. Berman B, Maderal A, Raphael B. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. *Dermatol Surg.* 2017;43:3–18.

3. Lv K, Xia Z. Chinese expert consensus on clinical prevention and treatment of scar. *Burns & trauma.* 2018;6:27.

4. Gangemi EN, Gregori D, Berchialla F, Zingarelli E, Cairo M, Bollero D, et al. Epidemiology and risk factors for pathologic scarring after burn wounds. *Arch Facial Plast Surg.* 2008;10:93–102.

5. Hultman CS, Edkins RE, Lee CN, Calvert CT, Cairns BA. Shine on: review of laser- and light-based therapies for the treatment of burn scars. *Dermatol Res Pract.* 2012;6:243651.

6. Boeve SA, Aaron LA, Martin-Herz SP, Peterson A, Cain V, Heimbach DM, et al. Sleep disturbance after burn injury. *J Burn Care Rehabil.* 2002;23:32–8.

7. Kwak IS, Choi YH, Jang YC, Lee YK. Immunohistochemical analysis of neuropeptides (protein gene product 9.5, substance P and calcitonin gene-related peptide) in hypertrophic burn scar with pain and itching. *Burns.* 2014;40:1661–7.

8. Forbes-Duchart L, Cooper J, Nedelec B, Ross L, Quanbury PA, Haldersdal M. Fractional CO2 laser treatment of caesarean section scars—a randomized controlled split-scar trial with long term follow-up assessment. *Laser Surg Med.* 2017;49:189–97.

9. Pilcher JJ, Ginter DR, Sadowsky B. Sleep quality versus sleep quantity: relationships between sleep and measures of health, well-being and sleepiness in college students. *J Psychosom Res.* 1997;42:583–96.

10. Berman B, Viera MH, Amini S, Hauo R, Jones IS. Prevention and management of hypertrophic scars and keloids after burns in children. *J Craniomaxillofac Surg.* 2008;19:989–1006.

11. Vincen V, Klinger M, Klinger FM, Forcellini D, Borbon G, Cavigioli F. Treatment outcomes for keloid scar management in the pediatric burn population. *Burns.* 2013;39:1321–32.

12. Steinstraesser L, Flak E, Witte B, Ring A, Tilkorn D, Hauser J, et al. Pressure garment therapy alone and in combination with silicone for the prevention of hypertrophic scarring: randomized controlled trial with intraindividual comparison. *Plast Reconstr Surg.* 2011;128:306–13.

13. Wiseman J, Simons M, Kimble R, Ware R, McPhail S, Tyack Z. Effectiveness of topical silicone gel and pressure garment therapy for burn scar prevention and management in children: study protocol for a randomised controlled trial. *Trials.* 2017;18:72.

14. Klinger M, Marazzi M, Vigo D, Torre M. Fat injection for cases of severe burn outcomes: a new perspective of scar remodeling and reduction. *Aesthetic Plastic Surg.* 2008;32:465–9.

15. Anderson RR, Donelan MB, Hivnor C, Greeran E, Ross EV, Shumaker PR, et al. Laser treatment of traumatic scars with an emphasis on ablative fractional laser resurfacing: consensus report. *JAMA Dermatol.* 2014;150:187–93.

16. Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. *Lasers Surg Med.* 2004;34:426–38.

17. Helbig B, Bodendorf MO, Grenewald S, Kendler M, Simon JC, Paasch U. Immunohistochemical investigation of wound healing in response to fractional photothermolysis. *J Biomed Opt.* 2009;14:604044.

18. Prignano F, Campolmi P, Bonan P, Ricceri F, Cannarozzo G, Troiano M, et al. Fractional CO2 laser: a novel therapeutic device upon photobiomodulation of tissue remodeling and cytokine pathway of tissue repair. *Dermatologic Ther.* 2009;22:8–15.

19. Ozog DM, Liu A, Chaffins ML, Ormsby AH, Fincher EF, Chipps LK, et al. Evaluation of clinical results, histological architecture, and collagen expression following treatment of mature burn scars with a fractional carbon dioxide laser. *JAMA Dermatol.* 2013;149:50–7.

20. Omi T, Numano K. The role of the CO2 laser and fractional CO2 laser in dermatology. *Laser Therapy.* 2014;23:49–60.

21. Oh BH, Hwang YJ, Lee YW, Choe YB, Ahn KJ. Skin characteristics after fractional photothermolysis. *Ann Dermatol.* 2017;29:434–54.

22. Hurliman E, Zelickson B, Kenkel J. In-vivo histological analysis of a fractional CO2 laser system intended for treatment of soft tissue. *J Drugs Dermatol.* 2017;16:1085–90.

23. Xiao Y, Sun Y, Zhu B, Wang K, Liang P, Liu W, et al. Risk factors for hypertrophic burn scar pain, pruritus, and paresthesia development. *Wound Repair Regen.* 2018;26:172–81.

24. Karmisholt KE, Taudorf EH, Wulff CB, Wenende E, Philipsen PA, Haedersdal M. Fractional CO2 laser treatment of caesarean section scars—a randomized controlled split-scar trial with long term follow-up assessment. *Laser Surg Med.* 2017;49:189–97.

25. Buyssse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. *Psychiatr Res.* 1989;28:193–213.

26. Langley GB, Shepperd H. The visual analogue scale: its use in pain measurement. *Rheumatol Int.* 1985;5:145–8.

27. Poquette N, Lin C. The brief pain inventory (BPI). *J Physiother.* 2016;62:52.

28. Furue M, Ebata T, Ikoma A, Takeuchi S, Kataoka Y, Takamori K, et al. Verbalizing extremes of the visual analogue scale for pruritus: a consensus statement. *Acta Derm-Venereol.* 2013;93:214–5.

29. Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. *Brit J Dermatol.* 2010;162:587–93.

30. Ghentner AR, Duclos K, Jahns BG, Krause E, Amann E, Limacher A, et al. Clinical scoring system for vulvar lichen sclerosus. *Journal of Sexual Med.* 2012;9:2342–50.

31. Yang AC, Yang CH, Hong CJ, Tsai S, Kuo C, Peng C, et al. Sleep state instabilities in major depressive disorder: detection and quantification with electrocardiogram-based cardiopulmonary coupling analysis. *Psychophysiology.* 2011;48:285–91.

32. Choi JH, Thomas RJ, Suh SY, Park IH, Kim TH, Lee SH, et al. Sleep quality change after upper airway surgery in obstructive sleep apnea: electrocardiogram-based cardiopulmonary coupling analysis. *Laryngoscope.* 2015;125:1737–42.

33. Thomas RJ, Mietus JE, Peng CK, Goldberger AL. An electrocardiogram-based technique to assess cardiopulmonary coupling during sleep. *Sleep.* 2005;28:1151–61.

34. Clayton JL, Edkins R, Cairns BA, Hultman CS. Incidence and management of adverse events after the use of laser therapies for the treatment of hypertrophic burn scars. *Ann Plas Surg.* 2013;70:500–5.

35. Gottschlich MM, Jenkins ME, Mayes T, Khoury J, Kramer M, Warden GD, et al. The 1994 clinical research award. A prospective clinical study of the polysomnographic stages of sleep after burn injury. *J Burn Care Rehabil.* 1994;15:486–92.

36. Bolton L. Evidence corner: taking itch seriously. *Wounds.* 2018;30:27–38.
37. Lee AF, Ryan CM, Schneider JC, Kazis LE, Li NC, Mary R, et al. Quantifying risk factors for long-term sleep problems after burn injury in young adults. *J Burn Care Res.* 2017;38: 510–20.

38. Qu L, Liu A, Zhou L, He C, Grossman PH, Moy RL, et al. Clinical and molecular effects on mature burn scars after treatment with a fractional CO₂ laser. *Laser Surg Med.* 2012;44:517–24.

39. Waibel JS, Wulkan AJ, Shumaker PR. Treatment of hypertrophic scars using laser and laser assisted corticosteroid delivery. *Laser Surg Med.* 2013;45:135–40.

40. Waibel JS, Wulkan AJ, Rudnick A, Daoud A. Treatment of hypertrophic scars using laser-assisted corticosteroid versus laser-assisted 5-fluorouracil delivery. *Dermatol Surg.* 2019;45:423–30.